IL-34 诱导抵抗射线放疗和奥沙利铂化疗等细胞毒性抗癌疗法的机制。
A mechanism of IL-34-induced resistance against cytotoxic anti-cancer therapies such as radiation by X-ray and chemotherapy by Oxaliplatin.
机构信息
Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
出版信息
Oncoimmunology. 2023 Jul 24;12(1):2238499. doi: 10.1080/2162402X.2023.2238499. eCollection 2023.
Interleukin-34 (IL-34) has been known as a factor that is involved with tumor progression and therapeutic resistance. However, there are limitations to addressing the mechanism of how IL-34 induces therapeutic resistance. Here, we show a mechanism of IL-34-induced resistance against cytotoxic anti-cancer therapies such as radiotherapy using X-ray and chemotherapy by Oxaliplatin. This research demonstrates that IL-34 immunologically changes the tumor microenvironment after treatments with radiation or chemotherapeutic agents such as oxaliplatin. We identified the changes in immune cells using flow cytometry and immunofluorescent (IF) staining, which are up-regulated upon the existence of IL-34. Overall, these findings demonstrate the possibility of IL-34 blockade as a novel combination therapy for cancer.
白细胞介素 34（IL-34）已被认为是参与肿瘤进展和治疗耐药的因素。然而，在解决 IL-34 如何诱导治疗耐药的机制方面存在局限性。在这里，我们展示了 IL-34 诱导对放射治疗和化学治疗（如奥沙利铂）等细胞毒性抗癌疗法产生耐药性的机制。这项研究表明，IL-34 在接受放射或化学治疗剂（如奥沙利铂）治疗后，在免疫上改变了肿瘤微环境。我们使用流式细胞术和免疫荧光（IF）染色来鉴定免疫细胞的变化，这些变化在 IL-34 的存在下上调。总的来说，这些发现表明 IL-34 阻断可能是癌症的一种新的联合治疗方法。
Zotero 插件